Drugs / eratrectinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04614740 | Nov 2020 → Jan 2024 | metastatic neoplasm | Jiangsu vcare pharmaceutical technology co., LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eratrectinib | “Eratrectinib (VC004) is a next-generation selective TRK TKI which can overcome drug resistance.” PMID 42351304 ↗ Jun 2026 |
| Known as | VC004 | “Eratrectinib (VC004) is a next-generation selective TRK TKI which can overcome drug resistance.” PMID 42351304 ↗ Jun 2026 |
| Route | Oral | “dose levels of oral eratrectinib” PMID 42351304 ↗ Jun 2026 |